Találati lista | Tudóstér

001-es BibID:	BIBFORM105439
035-os BibID:	(cikkazonosító)1940 (WoS)000902645500001 (Scopus)85144728705
Első szerző:	Llanaj, Erand (táplálkozási epidemiológus)
Cím:	Buckwheat and Cardiometabolic Health : a Systematic Review and Meta-Analysis / Llanaj Erand, Ahanchi Noushin Sadat, Dizdari Helga, Taneri Petek Eylul, Niehot Christa D., Wehrli Faina, Khatami Farnaz, Raeisi-Dehkordi Hamidreza, Kastrati Lum, Bano Arjola, Glisic Marija, Muka Taulant
Dátum:	2022
ISSN:	2075-4426
Megjegyzések:	Buckwheat (BW) is suggested to have beneficial effects, but evidence on how it affects cardiometabolic health (CMH) is not yet established. We aimed to assess the effects of BW and/or its related bioactive compounds on cardiovascular disease (CVD) risk markers in adults. Five databases were searched for eligible studies. Observational prospective studies, nonrandomized or randomized trials were considered if they assessed BW, rutin or quercetin-3-glucoside intake and CVD risk markers. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting. We selected 16 human studies based on 831 subjects with mild metabolic disturbances, such as hypercholesterolemia, diabetes and/or overweight. Eight studies, investigating primarily grain components, were included in the meta-analyses (n = 464). High study heterogeneity was present across most of our analyses. Weighted mean difference (WMD) for subjects receiving BW supplementation, compared to controls, were - 0.14 mmol/L (95% CI: -0.30; 0.02) for total cholesterol (TC), -0.03 mmol/L (95% CI: -0.22; 0.16) for LDL cholesterol, -0.14 kg (95% CI: -1.50; 1.22) for body weight, -0.04 mmol/L (95% CI: - 0.09;0.02) for HDL cholesterol, -0.02 mmol/L (95% CI: -0.15; 0.11) for triglycerides and -0.18 mmol/L (95% CI: -0.36; 0.003) for glucose. Most of the studies (66.7%) had concerns of risk of bias. Studies investigating other CVD markers were scarce and with inconsistent findings, where available. Evidence on how BW affects CMH is limited. However, the available literature indicates that BW supplementation in mild dyslipidaemia and type 2 diabetes may provide some benefit in lowering TC and glucose, albeit non-significant. Our work highlights the need for more rigorous trials, with better methodological rigor to clarify remaining uncertainties on potential effects of BW on CMH and its utility in clinical nutrition practice.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Journal of Personalized Medicine. - 12 : 12 (2022), p. 1-19. -
További szerzők:	Ahanchi, Noushin Sadat Dizdari, Helga Taneri, Petek Eylul Niehot, Christa D. Wehrli, Faina Khatami, Farnaz Raeisi-Dehkordi, Hamidreza Kastrati, Lum Bano, Arjola Glisic, Marija Muka, Taulant
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM106086
035-os BibID:	(cikkazonosító)1 (WOS)000908911400001 (Scopus)85145920793
Első szerző:	Valido, Ezra
Cím:	Systematic Review of Human and Animal Evidence on the Role of Buckwheat Consumption on Gastrointestinal Health / Valido Ezra, Stoyanov Jivko, Gorreja Frida, Stojic Stevan, Niehot Christa, Kiefte-de Jong Jessica, Llanaj Erand, Muka Taulant, Glisic Marija
Dátum:	2023
ISSN:	2072-6643
Megjegyzések:	Background: Buckwheat is a commonly cultivated crop with growing evidence that it is beneficial to gastrointestinal (GI) health. This systematic review summarizes the role of buckwheat in modifying GI health outcomes and microbiomes. Methods: Four medical databases and Google Scholar were systematically searched. Clinical trials, observational studies, animal in vivo, and in vitro studies with human and animal GI-derived samples were included. Results: There were 32 studies (one randomized controlled trial [RCT], one non-randomized trial, 3 observational, 9 in vitro, and 18 animal in vivo studies) included. In preclinical studies, buckwheat extracts were observed to have cytotoxic potential against human-derived GI cancer cell lines. Animals fed with buckwheat had lower GI mucosal inflammation, higher alpha diversity in the GI microbiome, and higher levels of fecal short-chain fatty acids. Human evidence studies and clinical trials were limited and predominantly of moderate risk of bias. The majority of in vitro studies with GI-derived samples and in vivo studies were reliable without restrictions in study design. Conclusion: In vivo and in vitro studies show that buckwheat may have potential GI benefits due to its anti-oxidant and anti-inflammatory potential; however, human evidence remains limited, and its impact on health in humans remains to be elucidated in future trials.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk buckwheat Tartary buckwheat gastrointestinal symptoms microbiome
Megjelenés:	Nutrients. - 15 : 1 (2023), p. 1-18. -
További szerzők:	Stoyanov, Jivko Gorreja, Frida Stojic, Stevan Niehot, Christa D. Kiefte-de Jong, Jessica Llanaj, Erand (1988-) (táplálkozási epidemiológus) Muka, Taulant Glisic, Marija
Pályázati támogatás:	NA Other
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: